Gefitinib resistance in HCC mahlavu cells: Upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation

Journal of Cellular Physiology

Volumn 227, Issue 7, 2012, Pages 2947-2952

  Bodzin, Adam S ^a   Wei, Zhengyu ^a   Hurtt, Reginald ^a   Gu, Tina ^a   Doria, Cataldo ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GEFITINIB; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL NUCLEUS; CELL SELECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAHLAVU CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TREATMENT OUTCOME; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84858685991     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.23041     Document Type: Article

References (29)

1. Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM. 2010. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70: 6412-6419.
2. Baege AC, Disbrow GL, Schlegel R. 2004. IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis. J Virol 78: 5720-5727.
3. Baserga R, Morrione A. 1999. Differentiation and malignant transformation: Two roads diverged in a wood. J Cell Biochem Suppl 32-33: 68-75.
4. Baserga R, Peruzzi F, Reiss K. 2003. The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877.
5. Bosch FX, Ribes J, Diaz M, Cleries R. 2004. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127: S5-S16.
6. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
7. Cabrera R, Nelson DR. 2009. Review article: Management of hepatocellular carcinoma. Aliment Pharmacol Ther
8. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. 2004. Obesity and hepatocellular carcinoma. Gastroenterology 127: S97-S103.
9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638.
10. Deng H, Lin Y, Badin M, Vasilcanu D, Stromberg T, Jernberg-Wiklund H, Sehat B, Larsson O. 2010. Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem Biophys Res Commun 404: 667-671.
11. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O. 2009. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15: 5445-5456.
12. El-Serag HB, Tran T, Everhart JE. 2004. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460-468.
13. Ernst M, Rodan GA. 1990. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): Positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 127: 807-814.
14. Hartog H, Wesseling J, Boezen HM, van der Graaf WT. 2007. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur J Cancer 43: 1895-1904.
15. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. 2006. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 71: 1435-1448.
16. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER. 2010. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10: 116.
17. Lau WY, Lai EC. 2008. Hepatocellular carcinoma: Current management and recent advances. Hepatobiliary Pancreat Dis Int 7: 237-257.
18. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. 2001. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808.
19. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. 2008. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
20. Massie C, Mills IG. 2006. The developing role of receptors and adaptors. Nat Rev Cancer 6: 403-409.
21. Redmond KM, Wilson TR, Johnston PG, Longley DB. 2008. Resistance mechanisms to cancer chemotherapy. Front Biosci 13: 5138-5154.
22. Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, Larsson O. 2010. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3: ra10.
23. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J. 2010. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
24. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T. 2010. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45: 896-902.
25. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, Nakagawara A, Kamijo T. 2011. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 30: 97-105.
26. Valentinis B, Baserga R. 2001. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 54: 133-137.
27. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. 2007. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 13: 1438-1444.
28. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. 2009. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-185.
29. Wong JB, McQuillan GM, McHutchison JG, Poynard T. 2000. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90: 1562-1569.